Analytical, anthropometric and dietary factors associated with the development of fibrosis in patients with nonalcoholic fatty liver disease

Cuesta, Sara Gómez de la; Fuente, Rocío Aller de la; Sánchez, Carla Tafur; Izaola, Olatz; Sánchez, Concepción García; Mora, Núria; Hernández, José Manuel González; Román, Daniel de Luis

doi:10.17235/reed.2018.5118/2017

Cited by 9 publications

(9 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There were no important sociodemographic differences between the groups compared, except in the age, which was higher in patients with significant fibrosis than in those without significant fibrosis. This finding coincides with other studies (31,32) which had already noted the relationship between older age and the presence of significant or advanced fibrosis.…”

Section: Discussionsupporting

confidence: 93%

Psychological Biomarkers and Fibrosis: An Innovative Approach to Non-alcoholic Fatty Liver Disease

et al. 2020

View full text Add to dashboard Cite

Background: It is unknown how perceived social support and the progression of liver damage influence the psychosocial profile of patients with non-alcoholic fatty liver disease (NAFLD). In the present study, we therefore investigated which biomarkers influence the quality of life, mental health, and coping strategies of NAFLD patients. Methods: Quality of life (SF-12 and CLDQ-NAFLD), mental health (HADS and BDI-II), and coping strategies (COPE-28) were evaluated by high or low perceived social support (MSPSS) and the presence of non-alcoholic steatohepatitis (NASH) and significant fibrosis in 492 biopsy-proven NAFLD patients. The results were compared with quality of life normality tables for the general Spanish population. We also determined whether liver histology and biopsychosocial variables predicted participants' quality of life. Results: Interactive effects were found in vitality (p = 0.05), activity (p = 0.005), anxiety (p = 0.04), and denial (p = 0.04), with NASH patients showing a higher-risk biopsychosocial profile when they perceived less social support. Furthermore, patients with low perceived social support showed lower quality of life, worse mental health, and more maladaptive coping than those with high perceived social support, regardless of NASH presence. Patients with significant fibrosis showed lower quality of life compared to those without or the general Spanish population. Patients with significant fibrosis also reported worse mental health and more maladaptive coping. Lastly, significant fibrosis, female sex, greater anxiety and depressive symptoms, and worse physical and mental health-related quality of life were found to be independent determinants of worse disease-specific quality of life in these patients. Conclusions: Low perceived social support, significant fibrosis, and female sex were independently associated with a higher-risk psychosocial profile in NAFLD. These findings support the role of psychological biomarkers based on quality of life, mental health, and coping strategies in the management of these patients and suggest the potential benefits of a psychological intervention.

show abstract

Section: Discussionsupporting

confidence: 93%

Psychological Biomarkers and Fibrosis: An Innovative Approach to Non-alcoholic Fatty Liver Disease

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Interestingly, in that study, the influence of weight change on fibrosis progression depended on baseline HOMA-IR value, i.e., it was greater in patients with HOMA-IR <2.5. Recently, in a retrospective study using histological verification in patients with NAFLD, the HOMA-IR value at the time of evaluation was closely associated with the degree of liver fibrosis at the same time in patients with NAFLD regardless of the presence of diabetes [ 21 – 23 ].…”

Section: Discussionmentioning

confidence: 99%

“…In patients with NAFLD proven by biopsy, regardless of diabetes, the baseline HOMA-IR can be an independent predictor of fibrosis progression [ 19 , 20 ], and the HOMA-IR at the time of diagnosis was associated with the stage of fibrosis [ 21 – 23 ]. Only 1 study reported the association between baseline HOMA-IR and the risk of fibrosis progression in patients with NAFLD as evaluated using a non-invasive scoring index regardless of the presence of diabetes; however, the main focus of the study was weight change, not HOMA-IR [ 24 ].…”

Section: Introductionmentioning

confidence: 99%

Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: A cohort study

Koo¹,

Lee

Jung

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

Background and aims Fibrosis progression is the most important prognostic factor, and insulin resistance is one of the main mechanisms associated with fibrosis progression in patients with nonalcoholic fatty liver disease (NAFLD). We evaluate the association between baseline insulin resistance and future fibrosis progression in patients with NAFLD without diabetes. Approach and results This retrospective longitudinal study with 8-year follow-up period included 32,606 (men, 83%) participants aged >20 years (average age, 38.0 years) without diabetes at baseline who completed at least two comprehensive health checkups from January 1, 2010 to December 31, 2018. NAFLD was diagnosed based on ultrasonography. The homeostasis model assessment of insulin resistance (HOMA-IR) was used to evaluate baseline insulin resistance. Fibrosis progression was assessed using the aspartate aminotransferase to platelet ratio index (APRI). The advanced liver fibrosis with an APRI value above the intermediate fibrosis probability (≥0.5) developed in a total of 2,897 participants during 136,108 person-years. 114 participants progressed to a high fibrosis probability stage (APRI >1.5) during 141,064 person-years. Using the lowest baseline HOMA-IR quartile group (Q1) as a reference, the multivariate-adjusted hazard ratio (HR) for development of advanced liver fibrosis (APRI ≥0.5) in the highest baseline HOMA-IR quartile group (Q4) was 1.95 (95% confidence interval [CI] 1.74–2.19; Model 4). And the HR for development of advanced liver fibrosis with high fibrosis probability was 1.95 (95% CI 1.10–3.46; Model 4). The positive association was maintained throughout the entire follow-up period. The baseline HOMA-IR model was superior to the baseline body mass index (BMI) model in predicting the progression of fibrosis probability. Conclusions In this longitudinal study, we found that the degree of baseline insulin resistance, assessed by HOMA-IR values, was positively associated with future fibrosis progression in patients with NAFLD without diabetes.

show abstract

“…It is important to think of NAFLD as a disease that exceeds the liver, with systemic involvement, subscribed in the context of other metabolic diseases (MS, DM, and dyslipidemia). In this way, early interventions could reduce cardiovascular risk and the events related to it, as well as reduce the progression of fibrosis and its complications, with great importance in mortality, especially in patients with less advanced disease [11,12].…”

Section: Discussionmentioning

confidence: 99%

Applicability of the New Criteria for Diagnosis of Metabolic Dysfunction-Associated Fatty Liver Disease (MALFD) in Patients with Non-Alcoholic Fatty Liver Disease

Martín¹,

Biliary²,

Romina³

et al. 2021

J Diabet Res Rev Rep

View full text Add to dashboard Cite

Introduction: Non-alcoholic fatty liver disease affects 1/3 to ¼ of the world’s population. Currently this pathology is being redefined by using the acronym MALFD (Metabolic Dysfunction-Associated Fatty Liver Disease) and the possibility of new criteria for its diagnosis is being discussed. Methodology: Prospective and descriptive studies carried out between July 2018 and June 2020 where the applicability of the new criteria in MAFLD diagnosis were valued. Patients with NAFLD (Non-alcoholic fatty liver disease) were enrolled in clinics specialized in this pathology. Results: Out of 172 patients enrolled, 96.4% (this represents a total of 165 patients) presented obesity, were over weighted and or presented Diabetes Mellitus. The rest of the patients (a total of 7) presented high blood pressure and or dyslipidemia. Moreover, it was observed that the higher the obesity index the higher the prevalence of Diabetes Mellitus. Conclusions: The criteria for the diagnosis of MAFLD are adaptable in patients with a diagnosis of NAFLD from the first consultation and allow the assessment of prognostic elements of the disease. This would allow us to intervene at very early stages which could impact patient’s prognosis

show abstract

Analytical, anthropometric and dietary factors associated with the development of fibrosis in patients with nonalcoholic fatty liver disease

Cited by 9 publications

References 18 publications

Psychological Biomarkers and Fibrosis: An Innovative Approach to Non-alcoholic Fatty Liver Disease

Psychological Biomarkers and Fibrosis: An Innovative Approach to Non-alcoholic Fatty Liver Disease

Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: A cohort study

Applicability of the New Criteria for Diagnosis of Metabolic Dysfunction-Associated Fatty Liver Disease (MALFD) in Patients with Non-Alcoholic Fatty Liver Disease

Contact Info

Product

Resources

About